NCT02429570: Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 80 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have well-controlled systemic disease or show no evidence of disease (NED)
Exclusions: Patients with known leptomeningeal metastases

Comments are closed.

Up ↑